Expression analysis of microRNAs and their target genes during experimental diabetic renal lesions in rats administered with ginsenoside Rb1 and trigonelline.

Xiaona Shao, Chen Chen, Chunsheng Miao, Xiaoyan Yu, Xiangjun Li, Jianan Geng, Dongyan Fan, Xueyuan Lin, Yan ShiPubMed 2019 · DOI

TL;DR

This study investigates the therapeutic potential of ginsenoside Rb1 and trigonelline, natural compounds, in mitigating diabetic nephropathy (DN) in rats. The research reveals that a combination of these compounds not only alleviates DN symptoms and pathological damage but also modulates specific microRNAs (miRNAs), particularly miR-3550, which in turn influences the Wnt/β-catenin signaling pathway, a key player in kidney disease progression.

What Problem Does This Paper Address?

Diabetic nephropathy (DN) is a severe microvascular complication of diabetes mellitus, often leading to end-stage renal disease. Current treatments primarily focus on managing blood glucose and pressure, with limited specific therapies for DN itself. This paper addresses the need for novel therapeutic strategies by exploring the protective effects of two natural compounds, ginsenoside Rb1 (from Panax ginseng) and trigonelline (from Trigonella foenum-graecum), against DN. Furthermore, it delves into the underlying molecular mechanisms, specifically the role of microRNAs and the Wnt/β-catenin signaling pathway, which are increasingly recognized as critical in the pathogenesis of kidney diseases.

Methods

The researchers employed a multi-faceted approach to assess the efficacy and mechanisms of ginsenoside Rb1 and trigonelline in a rat model of diabetic nephropathy.

  • Diabetic Model Induction: Wistar rats were made diabetic using a single intraperitoneal injection of streptozotocin (STZ).
  • Treatment Groups: Diabetic rats were divided into four groups: a DN control group (receiving tap water), a group treated with ginsenoside Rb1 (40 mg/kg), a group treated with trigonelline (20 mg/kg), and a combination group receiving both compounds (60 mg/kg, with a 2:1 ratio of Rb1 to trigonelline). A non-diabetic control group also received tap water. Treatments were administered daily via gavage for 12 weeks.
  • Biochemical and Renal Function Assessments: Standard assays were used to measure blood glucose, lipid profiles (TCHO, HDL-C, LDL-C, TG), urine output, kidney weight relative to body weight, blood urea nitrogen (BUN), and serum creatinine (CRE). Glucose tolerance tests were also performed.
  • Oxidative Stress Analysis: Levels of antioxidant enzymes (CAT, SOD, GSH-PX) and malondialdehyde (MDA), a marker of lipid peroxidation, were measured in serum and kidney tissues.
  • Histological Examinations: Kidney tissues were analyzed using Hematoxylin-Eosin (HE) and Periodic Acid-Schiff (PAS) staining to assess structural changes like mesangial expansion and extracellular matrix accumulation. Immunohistochemistry was used to evaluate the expression of fibronectin (FN) and type IV collagen (Col IV).
  • MicroRNA Profiling: MicroRNA microarray analysis was performed on renal cortical tissues to identify differentially expressed miRNAs in control, DN, and combination treatment groups.
  • Quantitative PCR (qPCR): Real-time qPCR was used to validate the expression levels of specific miRNAs identified by the microarray.
  • Target Gene Analysis: Bioinformatics tools (TargetScan, miRanda, PicTar) were used to predict target genes of the identified miRNAs.
  • Protein Expression Analysis: Immunohistochemistry and Western blotting were employed to assess the protein levels of Wnt and β-catenin in kidney tissues.

Datasets

Not discussed in the paper. The study utilized a Wistar rat model and collected biological samples (serum, kidney tissue) from these animals for analysis.

Key Insights and Ideas

  • Synergistic Protective Effect: The combination of ginsenoside Rb1 and trigonelline demonstrated a significantly greater protective effect against diabetic nephropathy compared to either compound alone. This suggests a synergistic interaction between these natural compounds.
  • Beyond Glycemic Control: While managing blood glucose is crucial, the study highlights that the benefits of these compounds extend to improving lipid metabolism and reducing oxidative stress, both key contributors to DN pathogenesis.
  • MicroRNAs as Key Regulators: The research identifies specific microRNAs (miR-3550, miR-92b-5p, miR-1306-3p, and miR-30d-5p) that are dysregulated in DN and modulated by the treatment. This underscores the role of miRNAs as critical players in the development and potential treatment of DN.
  • Wnt/β-catenin Pathway Involvement: The study strongly implicates the Wnt/β-catenin signaling pathway, which is known to be involved in renal fibrosis and injury, as a downstream target of the therapeutic intervention. The observed changes in Wnt and β-catenin protein levels correlate with the protective effects of the treatment.
  • miR-3550 as a Central Mediator: The paper proposes that miR-3550, whose expression is altered by the treatment, plays a significant role in mediating the protective effects, likely by influencing the Wnt/β-catenin pathway.

Key Results

  • Improved Renal Function: The combination treatment (Group C) significantly reduced 24-hour urine volume and kidney weight/body weight ratio, and improved serum BUN and CRE levels compared to the DN group.
  • Reduced Oxidative Stress: Treatment with ginsenoside Rb1 and trigonelline increased the activity of antioxidant enzymes (CAT, SOD, GSH-PX) and decreased MDA levels, indicating a restoration of the antioxidant defense system.
  • Alleviated Pathological Damage: Histological analysis showed reduced glomerular hypertrophy, mesangial expansion, and extracellular matrix accumulation in treated groups, with the most significant improvement seen in the combination group.
  • Differential miRNA Expression: Microarray analysis revealed significant differences in miRNA expression between control and DN groups, and between DN and combination treatment groups. Specifically, miR-3550 was upregulated in the DN group and downregulated by the combination treatment.
  • Modulation of Wnt/β-catenin Pathway: Both immunohistochemistry and Western blotting showed significantly increased expression of Wnt and β-catenin proteins in the DN group, which was markedly reduced in the combination treatment group, returning to levels similar to the control group.

Limitations and Future Work

  • miR-30d-5p Discrepancy: The study noted a discrepancy between microarray and qPCR results for miR-30d-5p, suggesting it might be a false positive in the microarray analysis. This highlights the importance of validation.
  • Target Gene Specificity: While miR-3550's target gene CTNNB1 (β-catenin) was identified, the target genes for other differentially expressed miRNAs (miR-92b-5p, miR-1306-3p) were not found in their database. Further investigation is needed to fully elucidate the miRNA-target interactions.
  • In Vivo vs. In Vitro: The study was conducted in an animal model. Future work could involve in vitro studies to further confirm the direct mechanisms of action of these compounds and miRNAs on renal cells.
  • Clinical Translation: While promising, the findings are from a rat model. Further research is needed to assess the safety and efficacy of ginsenoside Rb1 and trigonelline in human clinical trials for diabetic nephropathy.
  • Long-term Effects: The study was conducted over 12 weeks. Investigating the long-term effects of these compounds on DN progression would be valuable.

Summary updated

Abstract

<i>Purpose</i>: To appraise the curative effect of ginsenoside Rb1 and trigonelline in diabetic nephropathy and to analyze the expression analysis of microRNAs and their target genes during experimental diabetic renal lesions in rats. <i>Methods</i>: Wistar rats were made diabetic by intraperitoneal injection of 55 mg/kg streptozotocin. According to their fasting blood glucose values and initial body weight, diabetic rats were assigned to specific groups and treated as follows: DN group (tap water, n = 10), A group (ginsenoside Rb1, 40 mg/kg, n = 10), B group (trigonelline, 20 mg/kg, n = 10) and the C group (ginsenoside Rb1 and trigonelline, 60 mg/kg, m(ginsenoside Rb1) : m (trigonelline) = 2:1, n = 10). The control group was treated with tap water (n = 10). All rats were gavaged with drugs or tap water once daily for 12 weeks. <i>Results</i>: Renal dysfunction, oxidative stress, and pathological alteration were significantly alleviated by a combination of ginsenoside Rb1 and trigonellin (C group). Some miRNAs were expressed differentially in Con, DN, A and C groups. Results of immunohistochemistry and western blotting showed that Wnt and β-catenin were expressed differentially in Con, DN, and C groups. <i>Conclusion</i>: Ginsenoside Rb1 and trigonelline could prevent the development of diabetic renal lesions by regulating the expression of miR-3550 and further associating with the Wnt/β-catenin signaling.
BibTeX
@inproceedings{shao2019expression,
  author = {Xiaona Shao and Chen Chen and Chunsheng Miao and Xiaoyan Yu and Xiangjun Li and Jianan Geng and Dongyan Fan and Xueyuan Lin and Zhen Chen and Yan Shi},
  title = {{Expression analysis of microRNAs and their target genes during experimental diabetic renal lesions in rats administered with ginsenoside Rb1 and trigonelline.}},
  booktitle = {PubMed},
  year = {2019},
  doi = {10.1691/ph.2019.8903},
}
Figure